MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) – Research analysts at HC Wainwright issued their Q1 2024 earnings estimates for MiNK Therapeutics in a note issued to investors on Thursday, March 21st. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.17) per share for the quarter. HC Wainwright has a […]
MiNK Therapeutics (NASDAQ:INKT – Free Report) had its price objective decreased by HC Wainwright from $10.00 to $9.00 in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. MiNK Therapeutics Stock Down 2.2 % NASDAQ INKT opened at $0.87 on Thursday. The business has […]
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 29th, there was short interest totalling 41,300 shares, a decline of 76.4% from the February 14th total of 175,100 shares. Approximately 0.4% of the shares of the stock are […]
A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.
MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report)’s stock price rose 3.9% on Thursday . The company traded as high as $0.93 and last traded at $0.90. Approximately 19,847 shares changed hands during trading, a decline of 62% from the average daily volume of 52,718 shares. The stock had previously closed at $0.87. MiNK Therapeutics […]